ARES IMMUNOTHERAPY, INC.

Biotech · Private

CAR-T cell therapy engineered from a unique T cell subset with anti-apoptotic properties and enhanced persistence for solid tumor treatment

Grants
$370K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A novel T cell subset with increased potency and persistence for the treatment of solid tumors$369,916
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1772Deep Longevity——
1773Cell-free Bioinnovation Inc.——
1774Rescindo Therapeutics Inc——
1775ARES IMMUNOTHERAPY, INC.——
1776Calluna Pharma——
1777ONL Therapeutics, Inc.—$111M
1778Alpine Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.